Entero Therapeutics develops targeted, orally delivered therapies for gastrointestinal diseases, utilizing proprietary technologies such as latiglutenase for celiac disease, capeserod for gastroparesis, and adrulipase for exocrine pancreatic insufficiency. Their solutions aim to improve nutrient absorption and alleviate symptoms in patients suffering from various digestive disorders.
Funding
$4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many individuals suffer from gastrointestinal (GI) diseases that impair nutrient absorption and cause uncomfortable symptoms. Current treatments often lack targeted delivery and can be ineffective in addressing the underlying causes of these disorders. This results in a significant unmet need for therapies that can improve digestive function and alleviate symptoms in a more precise and efficient manner.
Solution
Entero Therapeutics develops targeted, orally delivered therapies designed to address the root causes of various gastrointestinal diseases. Their approach utilizes proprietary technologies to enhance drug delivery and improve therapeutic outcomes. The company's pipeline includes latiglutenase, a biotherapeutic for celiac disease designed to break down gluten; capeserod, a selective 5-HT4 receptor partial agonist for gastroparesis; and adrulipase, a recombinant lipase for exocrine pancreatic insufficiency. These therapies aim to improve nutrient absorption, reduce inflammation, and alleviate symptoms associated with digestive disorders.
Target Audience
The primary target audience includes patients suffering from gastrointestinal diseases such as celiac disease, gastroparesis, and exocrine pancreatic insufficiency, as well as healthcare providers specializing in gastroenterology.
Features
- Latiglutenase: An oral biotherapeutic designed to break down gluten and reduce celiac disease symptoms.
- Capeserod: A selective 5-HT4 receptor partial agonist being developed for multiple GI indications, including gastroparesis.
- Adrulipase: A recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in patients with exocrine pancreatic insufficiency.
- Targeted drug delivery: Utilizes proprietary technologies to enhance drug delivery to the GI tract.
- Orally delivered therapies: Provides convenient administration for patients.